MRK

Merck & Co (MRK) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov^[4], including 91 Phase 3^[1], 76 Phase 2^[2], 70 Phase 1^[3].

Trial NCT06655883^[5] evaluates Suvorexant in Insomnia with a target enrollment of 300 participants. Trial NCT05173987^[6] evaluates pembrolizumab in Endometrial Neoplasms with a target enrollment of 280 participants. Trial NCT06074588^[7] evaluates Sacituzumab tirumotecan in Non-small Cell Lung Cancer (NSCLC) with a target enrollment of 556 participants.

MRK has 3 Form 4 insider filings recorded at the SEC in the past 30 days^[8].